A Phase 2 interventional study of GLPG2737 and Placebo in Autosomal Dominant Polycystic Kidney Disease, sponsored by Galapagos NV. Terminated at 20 sites in 7 countries. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-08-22.
Sponsored by Galapagos NV · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Polycystic Kidney, Autosomal Dominant with a site in Italy — 5 open to participants now, 9 under way, none of them phase 3. Polycystic Kidney, Autosomal Dominant · Italy.
Among the 29 studies in Polycystic Kidney, Autosomal Dominant with a site in Italy, this one is the 16th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2020, is one of 4 in phase 2, and was the 17th registered.
185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.
Browse Polycystic Kidney, Autosomal Dominant studies →5 of the 29 studies in Polycystic Kidney, Autosomal Dominant with a site in Italy are open now. Recruiting first, the newest first:
Calico Life Sciences LLC · Sites in Italy, United States, Australia and 9 more countries
Ages 18–55
Mario Negri Institute for Pharmacological Research · Sites in Italy
Healthy volunteers
IRCCS Azienda Ospedaliero-Universitaria di Bologna · Sites in Italy
Ages 18+
Fondazione IRCCS Policlinico San Matteo di Pavia · Sites in Italy
Ages 18–75
Ospedale San Raffaele · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 12
First in 2006; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is above the median of 51 across 138 interventional studies indexed under Polycystic Kidney, Autosomal Dominant.
Median enrollment 128 across the 18 interventional studies, 100 across the 11 observational. Of the 18 that completed or were terminated, 9 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Galapagos NV, one of the names counted as Lakefront Biotherapeutics NV. Under that name alone:
Galapagos NV is the lead sponsor of 103 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 11 (79%) have results posted.
Lakefront Biotherapeutics NV has 1 study filed under Polycystic Kidney, Autosomal Dominant — fewer than ten, so there is no comparison to draw.
1 of the studies in Polycystic Kidney, Autosomal Dominant with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07016282Mario Negri Institute for Pharmacological ResearchSimulated and Synthetic Health Data: Improving Clinical Research on Rare Diseases. A Real-World Data Simulation of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Trials. A Retrospective, Observational Study | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in Polycystic Kidney, Autosomal Dominant with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an exploratory, randomized, double-blind, placebo-controlled, parallel group, multicenter, proof of concept study (Phase 2a), evaluating orally administered GLPG2737 for a double-blind (DB) treatment period of 52 weeks and 4 weeks of follow up as well as an open-label extension (OLE) treatment period of 52 weeks and 4 weeks of follow-up, in participants with rapidly progressing ADPKD.
Key Inclusion Criteria for the double-blind period of the study:
Rapidly progressive disease, defined as presence of all of the following:
Key Inclusion Criteria for the OLE period of the study:
Key Exclusion Criteria for the double-blind period of the study:
Key exclusion criteria for the OLE period of the study:
Note: Other protocol-defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 150 milligrams (mg) GLPG2737 capsules orally once daily for 52 weeks in the double-blind (DB) treatment period. Eligible participants were rolled over to an open-label extension (OLE) period to receive 150 mg GLPG2737 orally once daily for 52 weeks.
Drug: GLPG2737
Participants received placebo matched to GLPG2737 capsules orally once daily for 52 weeks in the DB treatment period. Eligible participants were rolled over to an OLE period to receive 150 mg GLPG2737 orally once daily for 52 weeks.
Drug: GLPG2737 · Drug: Placebo
Capsules administered orally
Matching placebo capsules administered orally
DB Period: Mean Percent Change From MRI Baseline in htTKV
htTKV is used in participants with ADPKD disease to predict the onset of renal insufficiency. htTKV was calculated using TKV (in mL) obtained from MRI divided by height (in m). MRI Baseline: For MRI assessments, all non-missing values before the first study drug administration in the study +14 days (included) was considered as the primary baseline definition. Results were derived by mean of the individual slopes (i.e. using all MRI performed between baseline and Week 52).
Time frame: MRI Baseline up to Week 52
DB Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
An AE is any untoward medical occurrence in a participant administered a study drug, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the study drug, whether or not considered related to it. A serious adverse event (SAE) is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results a congenital anomaly/birth defect or other medically important event. A TEAE was defined as an AE observed after starting administration of the study drug until 30 days after last DB dose or 1 day before OLE dose, whichever occurred first.
Time frame: From first dose to Week 56
DB Period: Mean Change From Baseline in eGFR
The eGFR is a test that measures level of kidney function and determines the stage of kidney disease. eGFR was based on CKD-EPI formula (2009) calculated from serum creatinine concentrations. Results were derived by mean of the individual slopes (i.e. using data between baseline and Week 52).
Time frame: Baseline up to Week 52
DB Period: Area Under the Plasma Concentration-Time Curve During a Dosing Interval (AUCtau) of GLPG2737 and Its Metabolite
AUC0-tau described the area under the curve limited to the end of a dosing interval. The metabolite of GLPG2737 is M4.
Time frame: Predose (within 30 minutes prior to dosing), 1, 1.5, 2, 3, 4, 5, 6, 7 hours post dose through Week 52
DB Period: Maximum Observed Plasma Concentration (Cmax) of GLPG2737 and Its Metabolite
Cmax is the maximum observed plasma concentration of the drug. The metabolite of GLPG2737 is M4.
Time frame: Predose (within 30 minutes prior to dosing), 1, 1.5, 2, 3, 4, 5, 6, 7 hours post dose through Week 52
Participants with autosomal dominant polycystic kidney disease (ADPKD) were enrolled. The study was conducted at 20 sites in 7 countries i.e. Belgium, Czech Republic, Germany, Italy, Netherlands, Poland, and Spain. Out of these 20 activated sites, 3 sites did not enroll any participants. 89 participants were screened, out of which 66 were randomized.
| Milestone | GLPG2737 During DB + During OLE | Placebo During DB + GLPG2737 During OLE |
|---|---|---|
| Started | 44 | 22 |
| Completed | 41 | 20 |
| Not completed | 3 | 2 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Non compliance with study drug | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Milestone | GLPG2737 During DB + During OLE | Placebo During DB + GLPG2737 During OLE |
|---|---|---|
| Started | 39 | 20 |
| Completed | 3 | 4 |
| Not completed | 36 | 16 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Study terminated by sponsor | 34 | 15 |
htTKV is used in participants with ADPKD disease to predict the onset of renal insufficiency. htTKV was calculated using TKV (in mL) obtained from MRI divided by height (in m). MRI Baseline: For MRI assessments, all non-missing values before the first study drug administration in the study +14 days (included) was considered as the primary baseline definition. Results were derived by mean of the individual slopes (i.e. using all MRI performed between baseline and Week 52).
| percent change | GLPG2737 During DB | Placebo During DB |
|---|---|---|
| DB Period: Mean Percent Change From MRI Baseline in htTKV | 8.18 (6.04 to 10.36) | 9.17 (6.05 to 12.38) |
An AE is any untoward medical occurrence in a participant administered a study drug, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the study drug, whether or not considered related to it. A serious adverse event (SAE) is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results a congenital anomaly/birth defect or other medically important event. A TEAE was defined as an AE observed after starting administration of the study drug until 30 days after last DB dose or 1 day before OLE dose, whichever occurred first.
| participants | GLPG2737 During DB | Placebo During DB |
|---|---|---|
| TEAEs | 44 | 22 |
| Serious TEAEs | 1 | 3 |
The eGFR is a test that measures level of kidney function and determines the stage of kidney disease. eGFR was based on CKD-EPI formula (2009) calculated from serum creatinine concentrations. Results were derived by mean of the individual slopes (i.e. using data between baseline and Week 52).
| mL/min/1.73 m^2 | GLPG2737 During DB | Placebo During DB |
|---|---|---|
| DB Period: Mean Change From Baseline in eGFR | -5.44 (-7.34 to -3.54) | -3.13 (-5.87 to -0.39) |
AUC0-tau described the area under the curve limited to the end of a dosing interval. The metabolite of GLPG2737 is M4.
| nanogram* hour per milliliter (ng*h/mL) | GLPG2737 During DB |
|---|---|
| GLPG2737 | 18500 (17500 to 19500) |
| Metabolite M4 | 18700 (17400 to 20200) |
Cmax is the maximum observed plasma concentration of the drug. The metabolite of GLPG2737 is M4.
| ng/mL | GLPG2737 During DB |
|---|---|
| GLPG2737 | 1160 (1110 to 1220) |
| Metabolite M4 | 873 (813 to 939) |
Collected over DB Period: From first dose to Week 56 OLE Period: From first dose to Week 56. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GLPG2737 During DB + During OLE | 0/44 (0%) | 3/44 (6.8%) | 44/44 (100%) |
| Placebo During DB | 0/22 (0%) | 3/22 (13.6%) | 22/22 (100%) |
| Placebo During DB + GLPG2737 During OLE | 0/20 (0%) | 2/20 (10%) | 15/20 (75%) |
| Event | GLPG2737 During DB + During OLE | Placebo During DB | Placebo During DB + GLPG2737 During OLE |
|---|---|---|---|
| Cyst ruptureGeneral disorders | 0/44 | 0/22 | 1/20 |
| Renal cystRenal and urinary disorders | 0/44 | 0/22 | 1/20 |
| Renal abscessInfections and infestations | 0/44 | 1/22 | 0/20 |
| Ventricular extrasystolesCardiac disorders | 0/44 | 1/22 | 0/20 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/44 | 1/22 | 0/20 |
| Hypertensive emergencyVascular disorders | 0/44 | 1/22 | 0/20 |
| Hepatic cyst infectionInfections and infestations | 1/44 | 0/22 | 0/20 |
| Renal cyst infectionInfections and infestations | 1/44 | 0/22 | 0/20 |
| DiarrhoeaGastrointestinal disorders | 1/44 | 0/22 | 0/20 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/44 | 0/22 | 0/20 |
| Event | GLPG2737 During DB + During OLE | Placebo During DB | Placebo During DB + GLPG2737 During OLE |
|---|---|---|---|
| COVID-19Infections and infestations | 21/44 | 5/22 | 1/20 |
| HeadacheNervous system disorders | 11/44 | 8/22 | 0/20 |
| HypertensionVascular disorders | 13/44 | 4/22 | 0/20 |
| Renal painRenal and urinary disorders | 8/44 | 6/22 | 2/20 |
| Dry mouthGastrointestinal disorders | 11/44 | 1/22 | 1/20 |
| Upper respiratory tract infectionInfections and infestations | 5/44 | 3/22 | 5/20 |
| NasopharyngitisInfections and infestations | 10/44 | 5/22 | 2/20 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 8/44 | 2/22 | 1/20 |
| Back painMusculoskeletal and connective tissue disorders | 8/44 | 4/22 | 0/20 |
| InfluenzaInfections and infestations | 8/44 | 2/22 | 1/20 |
Safety Analysis Set (SAS): All randomized participants who received at least one dose of study drug.
| Age, Continuous(years) | GLPG2737 During DB | Placebo During DB | Total |
|---|---|---|---|
| Mean | 40.6 ± 6.3 | 39.6 ± 6.2 | 40.3 ± 6.3 |
| Sex: Female, Male(Participants) | GLPG2737 During DB | Placebo During DB | Total |
|---|---|---|---|
| Female | 24 | 8 | 32 |
| Male | 20 | 14 | 34 |
| Ethnicity (NIH/OMB)(Participants) | GLPG2737 During DB | Placebo During DB | Total |
|---|---|---|---|
| Hispanic or Latino | 9 | 2 | 11 |
| Not Hispanic or Latino | 35 | 20 | 55 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | GLPG2737 During DB | Placebo During DB | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 44 | 22 | 66 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Height-Adjusted Total Kidney Volume(htTKV)(mL/m) | GLPG2737 During DB | Placebo During DB | Total |
|---|---|---|---|
| Mean | 1069.18 ± 438.06 | 1439.23 ± 737.67 | 1190.51 ± 575.26 |
| Estimated Glomerular filtration rate (GFR)(mL/min/1.73 m^2) | GLPG2737 During DB | Placebo During DB | Total |
|---|---|---|---|
| Mean | 55.5 ± 16.3 | 51.6 ± 15.6 | 54.2 ± 16.1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2020 to primary completion in Dec 2022, 25 months.
Results were first posted in Aug 2024, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GLPG-2737
Polycystic Kidney, Autosomal Dominant →